1. Mughal TI, Radich JP, Deininger MW, Apperley JF, Hughes TP, Harrison CJ, et al. Chronic myeloid leukemia: reminiscences and dreams. Haematologica 2016;101:541-58. [ DOI:10.3324/haematol.2015.139337] 2. Benchikh S, Bousfiha A, El Hamouchi A, Soro SGC, Malki A, Nassereddine S. Chronic myeloid leukemia: cytogenetics and molecular biology's part in the comprehension and management of the pathology and treatment evolution. Egypt J Med Hum Genet 2022;23:1-13. [ DOI:10.1186/s43042-022-00248-2] 3. Rostami G, Assad D, Ghadyani F, Hamid M, Karami A, Jalaeikhoo H, et al. Influence of glutathione S‐transferases (GSTM1, GSTT1, and GSTP1) genetic polymorphisms and smoking on susceptibility risk of chronic myeloid leukemia and treatment response. Mol Genet Genomic Med 2019;7:e00717. [ DOI:10.1002/mgg3.717] 4. Adnan Awad S, Kankainen M, Ojala T, Koskenvesa P, Eldfors S, Ghimire B, et al. Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia. Blood Adv 2020;4:546-59. [ DOI:10.1182/bloodadvances.2019000943] 5. Mohammadi F, Shafiei M, Assad D, Rostami G, Hamid M, Foroughmand AM. Impact of ABCB1 Gene Polymorphisms and Smoking on the Susceptibility Risk of Chronic Myeloid Leukemia and Cytogenetic Response. Iran Biomed J 2021;25:54-61. 6. Wu W, Xu N, Zhou X, Liu L, Tan Y, Luo J, et al. Integrative genomic analysis reveals cancer-associated gene mutations in chronic myeloid leukemia patients with resistance or intolerance to tyrosine kinase inhibitor. Onco Targets Ther 2020;13:8581-8591. [ DOI:10.2147/OTT.S257661] 7. Ernst T, La Rosée P, Müller MC, Hochhaus A. BCR-ABL mutations in chronic myeloid leukemia. Hematol Oncol Clin North Am 2011; 25: 997-1008. [ DOI:10.1016/j.hoc.2011.09.005] 8. Rostami G, Hamid M, Yaran M, Khani M , Karimipoor M. Incidence and clinical importance of BCR-ABL1 mutations in Iranian patients with chronic myeloid leukemia on imatinib. J Hum Genet 2015; 60: 253-258. [ DOI:10.1038/jhg.2015.11] 9. Elias MH, Baba AA, Husin A, Sulong S, Hassan R, Sim GA, et al. HOXA4 gene promoter hypermethylation as an epigenetic mechanism mediating resistance to imatinib mesylate in chronic myeloid leukemia patients. Biomed Res Int 2013;2013. [ DOI:10.1155/2013/129715] 10. Guru SA, Sumi MP, Mir AR, Beg MMA, Saxena A. Aberrant hydroxymethylation in promoter CpG regions of genes related to the cell cycle and apoptosis characterizes advanced chronic myeloid leukemia disease, poor imatinib respondents and poor survival. BMC Cancer 2022; 22:1-15. [ DOI:10.1186/s12885-022-09481-9] 11. Yang X, Wong MPM, Ng RK. Aberrant DNA methylation in acute myeloid leukemia and its clinical implications. Int J Mol Sci 2019;20:4576. [ DOI:10.3390/ijms20184576] 12. Amabile G, Di Ruscio A, Müller F, Welner RS, Yang H, Ebralidze AK, et al. Dissecting the role of aberrant DNA methylation in human leukaemia. Nat Commun 2015;6:1-10. [ DOI:10.1038/ncomms8091] 13. Jelinek J, Gharibyan V, Estecio MR, Kondo K, He R, Chung W, et al. Aberrant DNA methylation is associated with disease progression, resistance to imatinib and shortened survival in chronic myelogenous leukemia. PLoS One 2011;6:e22110. [ DOI:10.1371/journal.pone.0022110] 14. Wang Y-l, Qian J, Lin J, Yao D-m, Qian Z, Zhu Z-h, et al. Methylation status of DDIT3 gene in chronic myeloid leukemia. J Exp Clin Cancer Res 2010;29:54. [ DOI:10.1186/1756-9966-29-54] 15. Radin D, Hamid M, Kargar M, Jafarinia M. Hypermethylation of HOXA4 Gene Promoter and Its Potential Association with Disease Progression, Imatinib Resistance, High Sokal Score Risk, and Smoking among Chronic Myeloid Leukemia Patients. Russ J Genet 2023;59:S199-207. [ DOI:10.1134/S1022795423140090] 16. Qian J, Chen Z, Lin J, Wang W, Cen J. Decreased expression of CCAAT/enhancer binding protein ζ (C/EBPζ) in patients with different myeloid diseases. Leuk Res 2005;29:1435-41. [ DOI:10.1016/j.leukres.2005.05.020] 17. Musialik E, Bujko M, Kober P, Grygorowicz MA, Libura M, Przestrzelska M, et al. Comparison of promoter DNA methylation and expression levels of genes encoding CCAAT/enhancer binding proteins in AML patients. Leuk Res 2014;38:850-6. [ DOI:10.1016/j.leukres.2014.04.013] 18. Lin J, Wang Y-l, Qian J, Yao D-m, Zhu Z-h, Qian Z, et al. Aberrant methylation of DNA-damage-inducible transcript 3 promoter is a common event in patients with myelodysplastic syndrome. Leuk Res 2010;34:991-4. [ DOI:10.1016/j.leukres.2010.01.003] 19. Baccarani M, Deininger MW, Rosti G, Hochhaus A, Soverini S, Apperley JF, et al. European Leukemia Net recommendations for the Management of chronic myeloid leukemia. Blood 2013;122:872-884. [ DOI:10.1182/blood-2013-05-501569] 20. Miller S, Dykes D, Polesky H. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988;16:1215. [ DOI:10.1093/nar/16.3.1215] 21. Wojdacz TK, Borgbo T, Hansen LL. Primer design versus PCR bias in methylation independent PCR amplifications. Epigenetics 2009; 4: 231-4. [ DOI:10.4161/epi.9020] 22. Mir R, Ahmad I, Javid J, Farooq S, Yadav P, Zuberi M, et al. Epigenetic silencing of DAPK1 gene is associated with faster disease progression in India populations with Chronic Myeloid Leukemia. J Cancer Sci Ther 2013;5:144-149. [ DOI:10.4172/1948-5956.1000201] 23. Lee KWK, Pauzova Z. Cigarette smoking and DNA methylation. Front Genet 2013;4:132. [ DOI:10.3389/fgene.2013.00132] 24. Zong D, Liu X, Li J, Ouyang R, Chen P.The role of cigarette smoke induced epigenetic alterations in inflammation. Epigenetics Chromatin 2019;12:65 [ DOI:10.1186/s13072-019-0311-8] |
